May 15, 2017 10:28 AM EDTUpdated 12:57 PM

Ignyta jumps on an FDA ‘breakthrough’ nod for entrectinib; Thermo Fisher buying Patheon in $7.2B deal

Shehla Shakoor

Managing Director

→ Ignyta has fresh reason to focus more on entrectinib, its TRK inhibitor for the treatment of NTRK fusion-positive tumors. The FDA has handed out …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ignyta jumps on an FDA ‘breakthrough’ nod for entrectinib; Thermo Fisher buying Patheon in $7.2B deal

Shehla Shakoor

Managing Director

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

At Jefferies, all that manufacturers want to talk about is GLP-1s

Are programs with compounded GLP-1s safe for your population?

Igny­ta jumps on an FDA ‘break­through’ nod for en­trec­tinib; Ther­mo Fish­er buy­ing Patheon in $7.2B deal

Shehla Shakoor

Managing Director

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Ignyta jumps on an FDA ‘breakthrough’ nod for entrectinib; Thermo Fisher buying Patheon in $7.2B deal

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

At Jefferies, all that manufacturers want to talk about is GLP-1s

Are programs with compounded GLP-1s safe for your population?